GlassScriptPhysician profile
Joseph L Maddi
NPI 1992761266
$4,531.07
in general payments reported to CMS, 2019-2025
33 companies · $80.00 in 2025
The $80.00 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $304 · 2021: $833 · 2022: $931 · 2023: $1,057 · 2024: $824 · 2025: $80.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $797.26 | 2022-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Boston Scientific Corporation | $627.95 | 2021-2024 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.35 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $460.39 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $315.05 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Janssen Pharmaceuticals, INC | $204.99 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $195.05 | 2019-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $186.64 | 2019-2024 | |
| Pfizer INC. | $150.17 | 2019-2023 | |
| Amarin Pharma, INC. | $148.56 | 2019-2023 | |
| Medtronic Vascular, INC. | $90.44 | 2019 | |
| Baxter Healthcare | $89.12 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $77.04 | 2021-2023 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $69.83 | 2022-2024 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $62.93 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48.59 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $46.49 | 2022-2023 | |
| Glaxosmithkline, LLC. | $44.90 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Nestle Healthcare Nutrition INC. | $42.08 | 2021-2022 | |
| Esperion Therapeutics, INC. | $37.04 | 2020-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $35.19 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.74 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $34.29 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $34.21 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $29.07 | 2024 | Voquezna |
| Kestra Medical Technology Services, INC. | $23.48 | 2022 | |
| Daiichi Sankyo INC. | $21.82 | 2020 | |
| Shield Therapeutics INC | $19.74 | 2024 | |
| Amgen INC. | $19.34 | 2023 | Repatha, Otezla |
| Hikma Pharmaceuticals USA | $17.43 | 2023 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $17.01 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.50 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Maddi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.